• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

醛酮还原酶1B10的泛癌图谱显示，其在胃癌中的表达降低。

The pan-cancer landscape of aldo-keto reductase1B10 reveals that its expression is diminished in gastric cancer.

作者信息

Wu Anqi, Li Hao, Gao Mengnan, Liang Juan, Huang Jiaqi, Farrés Jaume, Cao Deliang, Li Guoqing

机构信息

Department of Clinical Research Center, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.

Hunan Province Key Laboratory of Basic and Clinical Pharmacological Research on Gastrointestinal Tumors, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.

出版信息

Front Immunol. 2024 Dec 6;15:1488042. doi: 10.3389/fimmu.2024.1488042. eCollection 2024.

DOI:10.3389/fimmu.2024.1488042
PMID:39712017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11659136/
Abstract

INTRODUCTION

Aldo-keto reductase 1B10 (AKR1B10) is a multifunctional enzyme, which is important in cancer development and progression, but the landscape of AKR1B10 in pan-cancers and in tumor microenvironment is unclear.

METHOD

This study integrated the sequencing data of 33 cancer types, including gastric cancer, from TCGA project to explored the expression pattern and genetic and epigenetic alterations of AKR1B10. The association of AKR1B10 expression with clinical progression of cancers was evaluated by Kaplan-Meier analysis; the potential role of AKR1B10 in tumor microenvironment (TME) and immune-related gene expression were analyzed by PURITY, ESTIMATE, TIMER and CIBERSORT algorithms. The expression of AKR1B10 and immune cell markers in gastric cancer were evaluated with multiplex immunofluorescence staining.

RESULT

Results indicated that AKR1B10 was highly expressed in the gastrointestinal tract in health donors, but the expression of AKR1B10 was significantly changed in most of cancer types, which may be ascribed to DNA methylation in its promoter. The AKR1B10 expression in cancers and its value in disease progression was bidirectional and functionally enriched in metabolism in pan-cancers. In tumor microenvironment, AKR1B10 was significantly correlated with immune cell infiltrations and immune gene expression. In the stomach, along with the diminishing of AKR1B10 expression, CD68+ macrophage increased and CD19+ B cell decreased in gastric cancer.

DISCUSSION

These data indicates that AKR1B10 may be an important factor in the development and progression and a potential therapeutic target for multiple cancers, but plays as a protector in the gastric tissues.

摘要

引言

醛酮还原酶1B10（AKR1B10）是一种多功能酶，在癌症发生和发展过程中起着重要作用，但AKR1B10在泛癌及肿瘤微环境中的情况尚不清楚。

方法

本研究整合了来自TCGA项目的33种癌症类型（包括胃癌）的测序数据，以探究AKR1B10的表达模式、基因及表观遗传改变。通过Kaplan-Meier分析评估AKR1B10表达与癌症临床进展的关联；采用PURITY、ESTIMATE、TIMER和CIBERSORT算法分析AKR1B10在肿瘤微环境（TME）中的潜在作用及免疫相关基因表达。用多重免疫荧光染色评估胃癌中AKR1B10和免疫细胞标志物的表达。

结果

结果表明，AKR1B10在健康供体的胃肠道中高表达，但在大多数癌症类型中其表达发生了显著变化，这可能归因于其启动子中的DNA甲基化。AKR1B10在癌症中的表达及其在疾病进展中的价值具有双向性，且在泛癌中功能上富集于代谢。在肿瘤微环境中，AKR1B10与免疫细胞浸润和免疫基因表达显著相关。在胃中，随着胃癌中AKR1B10表达的降低，CD68+巨噬细胞增加，CD19+B细胞减少。

讨论

这些数据表明，AKR1B10可能是癌症发生和发展的重要因素以及多种癌症的潜在治疗靶点，但在胃组织中起保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/0dc2d815c655/fimmu-15-1488042-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/0fb703154b46/fimmu-15-1488042-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/a4a32e42aec3/fimmu-15-1488042-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/f0df2c2c2923/fimmu-15-1488042-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/7b131b9a3ed2/fimmu-15-1488042-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/3ab8a3f1da3e/fimmu-15-1488042-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/44b76541537a/fimmu-15-1488042-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/4f40ee36e43d/fimmu-15-1488042-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/a88db24963b3/fimmu-15-1488042-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/9aaf30180c32/fimmu-15-1488042-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/0dc2d815c655/fimmu-15-1488042-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/0fb703154b46/fimmu-15-1488042-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/a4a32e42aec3/fimmu-15-1488042-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/f0df2c2c2923/fimmu-15-1488042-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/7b131b9a3ed2/fimmu-15-1488042-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/3ab8a3f1da3e/fimmu-15-1488042-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/44b76541537a/fimmu-15-1488042-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/4f40ee36e43d/fimmu-15-1488042-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/a88db24963b3/fimmu-15-1488042-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/9aaf30180c32/fimmu-15-1488042-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/832f/11659136/0dc2d815c655/fimmu-15-1488042-g010.jpg

相似文献

1
The pan-cancer landscape of aldo-keto reductase1B10 reveals that its expression is diminished in gastric cancer.醛酮还原酶1B10的泛癌图谱显示，其在胃癌中的表达降低。
Front Immunol. 2024 Dec 6;15:1488042. doi: 10.3389/fimmu.2024.1488042. eCollection 2024.
2
Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.醛酮还原酶作为肝细胞癌的早期生物标志物：动物模型与人类 HCC 的比较。
Dig Dis Sci. 2018 Apr;63(4):934-944. doi: 10.1007/s10620-018-4943-5. Epub 2018 Jan 30.
3
AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.AKR1B10 在肝细胞癌中的表达特征及其与临床病理特征和免疫微环境的关系。
Sci Rep. 2024 May 27;14(1):12149. doi: 10.1038/s41598-024-62323-5.
4
In Search for Inhibitors of Human Aldo-Keto Reductase 1B10 (AKR1B10) as Novel Agents to Fight Cancer and Chemoresistance: Current State-of-the-Art and Prospects.寻找人类醛酮还原酶1B10（AKR1B10）抑制剂作为抗癌和抗化疗耐药性的新型药物：当前技术水平与前景
J Med Chem. 2025 Jan 23;68(2):860-885. doi: 10.1021/acs.jmedchem.4c01116. Epub 2025 Jan 5.
5
Aldo-keto Reductase 1B10 Restrains Cell Migration, Invasion, and Adhesion of Gastric Cancer via Regulating Integrin Subunit Alpha 5.醛酮还原酶 1B10 通过调节整合素亚基α5 抑制胃癌细胞迁移、侵袭和黏附
Turk J Gastroenterol. 2023 Dec;34(12):1197-1205. doi: 10.5152/tjg.2023.22555.
6
AKR1B10 regulates M2 macrophage polarization to promote the malignant phenotype of gastric cancer.AKR1B10 调控 M2 巨噬细胞极化促进胃癌的恶性表型。
Biosci Rep. 2023 Oct 31;43(10). doi: 10.1042/BSR20222007.
7
AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition.AKR1B10 通过调节上皮-间充质转化抑制胃癌的增殖和迁移。
Aging (Albany NY). 2021 Sep 22;13(18):22298-22314. doi: 10.18632/aging.203538.
8
AKR1B10 and digestive tumors development: a review.醛糖还原酶1B10与消化系统肿瘤的发生发展：综述
Front Immunol. 2024 Dec 16;15:1462174. doi: 10.3389/fimmu.2024.1462174. eCollection 2024.
9
[Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].醛酮还原酶家族1B10通过p27/p-Rb信号通路参与肝癌细胞周期的调控
Zhonghua Gan Zang Bing Za Zhi. 2020 Oct 20;28(10):861-867. doi: 10.3760/cma.j.cn501113-20191113-00418.
10
CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.CBX7 通过调节 AKR1B10-ERK 信号通路抑制膀胱癌进展。
Cell Death Dis. 2021 May 25;12(6):537. doi: 10.1038/s41419-021-03819-0.

本文引用的文献

1
AKR1B10 regulates M2 macrophage polarization to promote the malignant phenotype of gastric cancer.AKR1B10 调控 M2 巨噬细胞极化促进胃癌的恶性表型。
Biosci Rep. 2023 Oct 31;43(10). doi: 10.1042/BSR20222007.
2
Neutrophil-activating therapy for the treatment of cancer.中性粒细胞激活治疗癌症。
Cancer Cell. 2023 Feb 13;41(2):356-372.e10. doi: 10.1016/j.ccell.2023.01.002. Epub 2023 Jan 26.
3
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.免疫检查点阻断反应、耐药性和毒性的特征。
Cell. 2022 Feb 3;185(3):576. doi: 10.1016/j.cell.2022.01.008.
4
Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma.非达司他通过降低AKR1B10表达诱导自然杀伤细胞糖酵解以抑制肝细胞癌。
Mol Ther Oncolytics. 2021 Jun 12;23:420-431. doi: 10.1016/j.omto.2021.06.005. eCollection 2021 Dec 17.
5
AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition.AKR1B10 通过调节上皮-间充质转化抑制胃癌的增殖和迁移。
Aging (Albany NY). 2021 Sep 22;13(18):22298-22314. doi: 10.18632/aging.203538.
6
IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures.IOBR：多组学免疫肿瘤生物学研究解码肿瘤微环境和特征。
Front Immunol. 2021 Jul 2;12:687975. doi: 10.3389/fimmu.2021.687975. eCollection 2021.
7
Impaired Barrier Function and Immunity in the Colon of Aldo-Keto Reductase 1B8 Deficient Mice.醛酮还原酶1B8缺陷小鼠结肠中屏障功能和免疫受损
Front Cell Dev Biol. 2021 Feb 12;9:632805. doi: 10.3389/fcell.2021.632805. eCollection 2021.
8
Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.通过特定基因表达模式预测非酒精性脂肪性肝病进展及免疫失调
Front Immunol. 2021 Jan 26;11:609900. doi: 10.3389/fimmu.2020.609900. eCollection 2020.
9
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.非酒精性脂肪性肝病谱中的转录组特征分析揭示了肝脂肪变性和纤维化的基因特征。
Sci Transl Med. 2020 Dec 2;12(572). doi: 10.1126/scitranslmed.aba4448.
10
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.肿瘤免疫微环境与免疫评分在癌症预后和治疗疗效中的作用
Nat Rev Cancer. 2020 Nov;20(11):662-680. doi: 10.1038/s41568-020-0285-7. Epub 2020 Aug 4.